Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
19 results
D3.84 - Delayed hypersensitivity to hydroxychloroquine with positive patch test
D3.85 - Evaluation of a new Multiplex Allergen Test Kit for the simultaneous detection of allergen specific IgE
D3.87 - Assessing the agreement between skin prick test and specific-IgE for ten common food allergens in infants
D3.89 - Unexpected Culprit: The Role of Acrylates in Recurrent Anaphylaxis and Antibiotic Hypersensitivity
D3.91 - Safety of Skin Prick Tests: more than 30 years of spontaneous data from real practice
D3.94 - Optimizing the Diagnosis and Treatment of Psoriasis Associated with Streptococcal Infection
D3.88 - 5-Year Metal Patch Testing Analysis of a Portuguese Immunology an Allergology Center: Allergen relevance and Cluster identification
D2.351 - Relapse Rate and Risk Factors After Omalizumab Treatment in Adolescents with Chronic Spontaneous Urticaria
D2.352 - Assessing Risk Factors for Relapse Following Omalizumab Discontinuation in Chronic Urticaria
D2.353 - A Single Dose of Briquilimab, An Anti-Human CD117 (c-Kit) Antibody, Protects Against Relapse of Epicutaneous Allergen-Induced Dermatitis in Mice Expressing Chimeric Human/Mouse CD117
D2.354 - Questionnaire survey of new treatments for atopic dermatitis
D2.355 - Concurrent use of dupilumab and omalizumab in severe atopic dermatitis and severe chronic urticaria
D2.356 - Real-life effectiveness of omalizumab and its impact on quality of life in patients with chronic spontaneous urticaria
D2.357 - Characterizing chronic histaminergic angioedema and chronic urticaria with angioedema, a multicenter Italian experience
D2.358 - Immune shift toward the IL-17 pathway: A case of paradoxical psoriasis in a patient with severe atopic dermatitis induced by dupilumab
D2.359 - Safety and effectiveness of Omalizumab for Cold Urticaria in pediatric age
D2.362 - Dual biological therapy with dupilumab and ixekizumab in a patient with asthma, nasal polyposis, atopic dermatitis and psoriasis
D2.363 - Lanadelumab Effect on Hereditary Angioedema Activity Score: A Tertiary Center Experience
D2.364 - Omalizumab Use in Pediatric Chronic Urticaria, A Retrospective Study from a Tertiary Hospital
Download the app
The congress at your fingertips
Available on
Download